WuXi NextCODE expanding Illumina sequencing capabilities
/WuXi NextCODE Launches New State-of-the-art Genetic Analysis Laboratory in U.S. with Illumina's New TruSight 500™ Assay
CAMBRIDGE, Mass. and SHANGHAI, March 30, 2019 /PRNewswire/ -- WuXi NextCODE, a global genomic data and insights company, is expanding its laboratory footprint into the U.S. with the opening of a state-of-the-art, CLIA-certified and CAP-accredited genetic analysis laboratory in Woburn, Massachusetts. The new laboratory is geographically close to WuXi NextCODE's U.S. office in Cambridge, Massachusetts.
"This new laboratory helps us provide our customers with the access to next generation sequencing for clinical trials around the world, under the roof of one single, highly respected organization," says Rob Brainin, Chief Executive Officer of WuXi NextCODE. "Our global lab footprint also ensures a seamless unified workflow with a single chain of custody, from sample management, standard operating procedures, rigorous implementation of quality systems, to analytics and standardized reporting, in the U.S., Asia and the E.U."
As the first CAP/CLIA/ISO 15189 certified laboratory in China, the company's Shanghai laboratory already offers comprehensive next generation sequencing (NGS) clinical and discovery research services. WuXi NextCODE has also recently acquired a large scale NGS laboratory in Dublin, Ireland, which is already CAP-accredited and anticipated to be CLIA-certified in the third quarter of 2019.
